Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Forest Namenda Has 10% Off-Label Use In Mild-To-Moderate Alzheimer’s

  • News

Executive Summary

Forest's Alzheimer's disease agent Namenda has 10% off-label use based on early launch data

You may also be interested in...



Forest Sees “Moderate” Namenda Growth Opportunity In Mild Alzheimer’s

Forest expects approval of its Namenda sNDA for the treatment of mild-to-moderate Alzheimer's disease to generate a "modest uptick" in prescription volume in the second half of the year

Forest Sees “Moderate” Namenda Growth Opportunity In Mild Alzheimer’s

Forest expects approval of its Namenda sNDA for the treatment of mild-to-moderate Alzheimer's disease to generate a "modest uptick" in prescription volume in the second half of the year

Forest Expects Lexapro To Gain Market Share Despite Lilly Cymbalta Launch

Forest is expecting continued market share gains for Lexapro as it prepares for the upcoming launch of Lilly's antidepressant Cymbalta

Table

View full table

Tags:
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS043811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By